Wockhardt (WOCKPHARMA) Q1 25/26 earnings summary

Executive summary

• Consolidated revenue from operations for Q1 FY26 was ₹738 crore, nearly flat year-over-year and sequentially from Q4 FY25.

• The group reported a consolidated net loss after tax of ₹108 crore for Q1 FY26, significantly higher than the ₹16 crore loss in Q1 FY25, mainly due to an exceptional impairment charge.

• Standalone results showed a net profit after tax of ₹69 crore for Q1 FY26, up from ₹6 crore in Q1 FY25.

Financial highlights

• Consolidated total income for Q1 FY26 was ₹758 crore, compared to ₹769 crore in Q1 FY25.

• Exceptional item of ₹97 crore was recorded as an impairment charge related to the US business exit.

• Standalone total income for Q1 FY26 was ₹438 crore, up from ₹379 crore in Q1 FY25.

• Standalone EPS (basic and diluted) for Q1 FY26 was ₹4.25, compared to ₹0.39 in Q1 FY25.

Outlook and guidance

• The group has exited the US generic pharmaceutical segment, filing for voluntary liquidation of its US subsidiaries.

• Management has recognized impairment losses and is focused on winding up US operations.